PharmaCyte Biotech
PMCB
28 hedge funds and large institutions have $712K invested in PharmaCyte Biotech in 2025 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 1 closing their positions.
600% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 1
70% more capital invested
Capital invested by funds: $420K → $712K (+$292K)
22% more funds holding
Funds holding: 23 → 28 (+5)
3.33% more ownership
Funds ownership: 6.38% → 9.71% (+3.3%)
29% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$194K |
| 2 |
HF
HRT Financial
New York
|
+$165K |
| 3 |
SM
Sabby Management
Miami Beach,
Florida
|
+$90K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$22.3K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$54.5K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$2.48K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$588 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$202 |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$20 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MA
26
MCF Advisors
Covington,
Kentucky
| $1 | +$1 | +1 | New |
|
27
Citigroup
New York
| – | -$1 | -1 | Closed |
|
PMCB Hedge Fund Activity: Q4 2025 in Review
28 of the 8,245 institutional investors tracked by Wall St. Rank reported a position in PharmaCyte Biotech (PMCB) for Q4 2025, worth a combined $712K — up 70% from $420K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new PMCB positions and 1 closed out — a net gain of 6 holders — while 5 added to existing stakes and 7 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $194K. The largest seller was Equitec Proprietary Markets, cutting an estimated $54.5K.
- 28 institutional investors held PharmaCyte Biotech (PMCB) as of Q4 2025, up from 23 in Q3 2025.
- Funds reported $712K of PharmaCyte Biotech stock for Q4 2025, up 70% quarter-over-quarter.
- 7 funds opened new PharmaCyte Biotech positions in Q4 2025 and 1 closed out, a net change of +6 holders.
- The largest PharmaCyte Biotech buyer in Q4 2025 was Citadel Advisors, an estimated $194K added.
- The largest PharmaCyte Biotech seller in Q4 2025 was Equitec Proprietary Markets, an estimated $54.5K sold.
Based on aggregated 13F filings for Q4 2025.